Drug Approval | November 30, 2022
AstraZeneca’s Dapagliflozin receives CDSCO approval
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
The company is in the process of appointing a new CFO.
The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
The only definitive way to diagnose and stage lung cancers is through biopsies
Total investment envisaged in this project stands at up to Rs 70 crore
Government of India has granted a patent for invention entitled "An improved safe process for the preparation of Sartan drugs of Formula I".
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
Subscribe To Our Newsletter & Stay Updated
